Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis

Gao, Fenghua; Zhang, Tingting; Liu, Hengqi; Li, Wei; Liu, Xianming; Qiu, Lihua; Li, Lanfang; Zhou, Shunhua; Qian, Zhengzi; Dong, Sitong; Zhao, Shuo; Li, Linyu; Zhang, Huilai

doi:10.1007/s00277-022-04914-8

Cited by 5 publications

(2 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The characteristic distribution of MF has contributed to the idea that sunlight and vitamin D might have a preventive effect against CTCL [ 28 , 29 , 30 ]. The notion was further accentuated by the recent discovery of an association between vitamin D deficiency and the risk of disease progression in other types of lymphoma [ 31 , 32 , 33 ] and a recent case study on juvenile CTCL and hypovitaminosis D [ 34 ].…”

Section: Sunlight Vitamin D and Cutaneous T-cell Lymphomamentioning

confidence: 99%

Vitamin D in Cutaneous T-Cell Lymphoma

Ødum,

Geisler

2024

Cells

View full text Add to dashboard Cite

Cutaneous T-cell lymphoma (CTCL) is characterized by the proliferation of malignant T cells in inflamed skin lesions. Mycosis fungoides (MF)—the most common variant of CTCL—often presents with skin lesions around the abdomen and buttocks (“bathing suit” distribution), i.e., in skin areas devoid of sun-induced vitamin D. For decades, sunlight and vitamin D have been connected to CTCL. Thus, vitamin D induces apoptosis and inhibits the expression of cytokines in malignant T cells. Furthermore, CTCL patients often display vitamin D deficiency, whereas phototherapy induces vitamin D and has beneficial effects in CTCL, suggesting that light and vitamin D have beneficial/protective effects in CTCL. Inversely, vitamin D promotes T helper 2 (Th2) cell specific cytokine production, regulatory T cells, tolerogenic dendritic cells, as well as the expression of immune checkpoint molecules, all of which may have disease-promoting effects by stimulating malignant T-cell proliferation and inhibiting anticancer immunity. Studies on vitamin D treatment in CTCL patients showed conflicting results. Some studies found positive effects, others negative effects, while the largest study showed no apparent clinical effect. Taken together, vitamin D may have both pro- and anticancer effects in CTCL. The balance between the opposing effects of vitamin D in CTCL is likely influenced by treatment and may change during the disease course. Therefore, it remains to be discovered whether and how the effect of vitamin D can be tilted toward an anticancer response in CTCL.

show abstract

Section: Sunlight Vitamin D and Cutaneous T-cell Lymphomamentioning

confidence: 99%

Vitamin D in Cutaneous T-Cell Lymphoma

Ødum,

Geisler

2024

Cells

View full text Add to dashboard Cite

show abstract

“…However, about 20%–25% of patients will have significantly shorter progression-free survival (PFS) and early progression after chemoimmunotherapy within the first 2 years from initial treatment (POD24). These patients have been shown to have poor long-term outcomes and reduced overall survival (OS) ( 6 ). Additionally, the treatment of relapsed/refractory (R/R) FL after ≥2 lines of prior therapy is associated with progressive shortening of PFS with each line of treatment ( 7 – 9 ).…”

Section: Introductionmentioning

confidence: 99%

The treatment of follicular lymphoma with CD19-directed chimeric antigen receptor T-cell therapy

Jacobs,

Jacobson

2024

Front. Oncol.

View full text Add to dashboard Cite

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Significant unmet need remains for patients with relapsed/refractory FL after ≥3 lines of prior therapy. While recent advancements have likely improved the survival of patients with FL, most patients will eventually relapse. The treatment of patients with FL after multiple relapses or those with refractory disease has historically led to lower overall response rates (ORR) and shorter progression-free survival (PFS) with each subsequent line of therapy. New treatments with high ORR and durable PFS are needed in this setting, particularly in patients that progress within 2 years of first line chemoimmunotherapy (POD24) and/or those refractory chemoimmunotherapy. Chimeric antigen receptor T-cell therapies targeting the B-cell antigen CD-19 have shown to be an efficacious treatment option for both heavily pretreated patients and/or patients with refractory FL, resulting in a high ORR and durable remissions.

show abstract

Effect of POD24 on the prognosis of follicular and other indolent B-cell non-hodgkin lymphomas

Li,

Wang

2024

Ann Hematol

View full text Add to dashboard Cite

Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis

Cited by 5 publications

References 52 publications

Vitamin D in Cutaneous T-Cell Lymphoma

Vitamin D in Cutaneous T-Cell Lymphoma

The treatment of follicular lymphoma with CD19-directed chimeric antigen receptor T-cell therapy

Effect of POD24 on the prognosis of follicular and other indolent B-cell non-hodgkin lymphomas

Contact Info

Product

Resources

About